Olvion Contraindications

Hypersensitivity to sildenafil citrate or to any of the excipients of Olvion.
Consistent with its known effects on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway (see Pharmacology: Pharmacodynamics under Actions), sildenafil was shown to potentiate the hypotensive effects of nitrates and its co-administration with nitric oxide donors (eg, amyl nitrite) or nitrates in any form is therefore contraindicated.
Agents for the treatment of erectile dysfunction, including sildenafil, should not be used in men for whom sexual activity is inadvisable (eg, patients with severe cardiovascular disorders eg, unstable angina or severe cardiac failure).
Olvion is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see Precautions).
The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: severe hepatic impairment, hypotension (blood pressure <90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders eg, retinitis pigmentosa (a minority of these patients has genetic disorders of retinal phosphodiesterases).